bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.03.14.643306

Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer's Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus Triggers

Georgiou, A.·Zanos, P.·Onisiforou, A.
View original source ↗Export metadata ↓

Abstract

Alzheimers disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping pathological mechanisms, with DM2 increasing AD risk. Disease-modifying therapies (DMTs) for DM2, including Metformin and Semaglutide, have been explored for neuroprotection, yet their efficacy in AD remains unclear. Here, we introduce a novel integrative framework combining comparative network pharmacology, Mendelian Randomization (MR), and transcriptomic validation to systematically assess the therapeutic impact of 39 DM2 DMTs in preventing AD in DM2. Metformin emerged as the top-ranked therapy, whereas Semaglutide ranked among the least effective based on comparative analysis within the DM2-AD pathway-pathway comorbidity network. Notably, a two-sample MR analysis finds no evidence supporting a genetic liability to either drug being associated with AD risk, suggesting that their benefits may arise through non-direct mechanisms or that their relationship could be confounded by third factors. Metformins neuroprotective impact is mediated through AMPK, insulin, and adipocytokine signaling, which regulate key AD-related processes. Additionally, Metformin may indirectly affect herpesviruses, emerging environmental contributors to AD, potentially enhancing its neuroprotective effects. In contrast, Semaglutide, despite its growing clinical prominence as a weight loss therapy, exhibits minimal engagement with core neurodegenerative pathways within the DM2-AD comorbidity network, highlighting variability in neuroprotective potential across DM2 DMTs. Furthermore, specific dual-action therapies (e.g., Insulin Glargine and Lixisenatide, Insulin Degludec and Liraglutide) exhibit efficacy comparable to Metformin, reinforcing the need for a precision medicine approach. These findings challenge the assumption that all DM2 DMTs confer equal neuroprotection, revealing significant differences in their impact on AD-related pathways. While some show strong potential for AD prevention, others appear far less effective. Metformins effects depend on genotype, disease state, and environmental factors, underscoring the need to re-evaluate DM2 DMTs for AD prevention in population-specific clinical trials. Metformin stands out as a strong candidate for targeted investigations in DM2 patients at high risk of AD.

Explore related subjects

bioinformaticsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Georgiou, A., Zanos, P., Onisiforou, A.. 2025-03-17. Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer's Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus Triggers. https://doi.org/10.1101/2025.03.14.643306

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Senescence-associated KRAS upregulation in peripheral T cells links to premature coronary artery disease

Aims: Premature coronary artery disease (PCAD) lacks specific molecular drivers, and the role of immunosenescence is unclear. We investigated whether aging-related gene dysregulation in T cells contributes to PCAD. Methods: We combined bulk transcriptomics of PBMCs from 12 PCAD patients and 21 controls, single-cell RNA sequencing of PBMCs and human atherosclerotic plaques, weighted gene co-expression network analysis, gene perturbation network analysis, and molecular docking. Results: KRAS was identified as a hub gene intersecting PCAD-associated genes and aging-related genes. Single-cell analysis showed KRAS upregulation predominantly in effector CD8+ T cells, which exhibited the highest senescence scores that were further elevated in disease. Network perturbation of KRAS strongly impacted the cell killing pathway. KRAS-high effector CD8+ T cells were detected in coronary and carotid plaques, displaying enhanced cytotoxicity, exhaustion, and senescence features. Additionally, a candidate small molecule was computationally predicted to bind inactive KRAS. Conclusions: Elevated KRAS expression in senescent, cytotoxic CD8+ T cells is associated with PCAD, bridging immunosenescence and premature atherosclerosis. This finding provides a novel biomarker candidate and potential therapeutic entry point, awaiting further functional validation.

bioinformatics↗
bioRxiv2026

Targeted finetuning enables co-folding models to learn ligand-induced protein conformational states

Advances in protein structure prediction have enabled all-atom protein-ligand co-folding models that predict bound conformations directly from sequence and small-molecule structure. However, these models often fail to generalize to novel binding sites or alternative protein conformational states, limiting their utility for chemical biology and drug discovery. Here we show this limitation reflects training data bias rather than architectural constraints and can be overcome through targeted finetuning. Using ten previously unseen X-ray structures of Werner (WRN) helicase from a drug discovery program, we finetune Boltz-1 to learn both an allosteric binding site and a large conformational change locking the enzyme in an inactive state, while preserving accuracy on the ATP-bound state. The finetuned model generalizes to different chemical series and transfers the conformational logic across RecQ-family helicases in a binding-site sequence-dependent manner. This approach provides a blueprint for adapting foundation models as new structural and mechanistic data emerge, enabling co-folding networks to capture ligand-induced conformational switches and binding poses absent from their training data but central to biological regulation and therapeutic intervention.

bioinformatics↗
bioRxiv2026

Benchmarking single-cell foundation models for aging biology

Single cell foundation models (scFMs) provide representations of cellular states, but their utility across biological questions in aging research remains unclear. We established a benchmark of cellular representations for aging research, evaluating ten general-purpose scFMs, three aging-specific models and conventional methods across five biological questions using more than 2.5 million single cell transcriptomes. Using frozen pretrained representations, Geneformer performed best among scFMs for chronological age prediction and age pseudotime concordance, although 2,000 highly variable genes achieved higher mean performance. Several scFMs captured positive molecular age shifts across three disease contexts, consistent with reported aging-associated changes. SCimilarity performed well for rare cellular state identification across out-of-distribution datasets, exceeding aging specific models and conventional baselines. At the gene level, scGPT showed the highest recovery of reference TF target interactions, including aging-related regulatory hubs. Overall, scFMs supported diverse aging analyses, but performance depended on the biological question, highlighting their utility for rare cellular state identification and regulatory analysis.

bioinformatics↗